Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the ten research firms that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $16.22.
A number of research firms recently issued reports on FOLD. UBS Group lifted their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Friday, May 2nd. The Goldman Sachs Group lowered their target price on Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a report on Friday, May 2nd. Finally, Wall Street Zen lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a report on Monday, May 5th.
Check Out Our Latest Stock Report on Amicus Therapeutics
Hedge Funds Weigh In On Amicus Therapeutics
Institutional investors have recently bought and sold shares of the stock. Virtus Fund Advisers LLC purchased a new position in Amicus Therapeutics in the 4th quarter worth about $29,000. Strs Ohio purchased a new position in Amicus Therapeutics in the 1st quarter worth about $30,000. Covestor Ltd grew its stake in Amicus Therapeutics by 114.9% during the 4th quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock valued at $41,000 after acquiring an additional 2,312 shares in the last quarter. PNC Financial Services Group Inc. grew its stake in Amicus Therapeutics by 211.4% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock valued at $42,000 after acquiring an additional 3,497 shares in the last quarter. Finally, BI Asset Management Fondsmaeglerselskab A S purchased a new position in Amicus Therapeutics during the 1st quarter valued at about $53,000.
Amicus Therapeutics Stock Performance
Shares of NASDAQ FOLD traded down $0.21 during midday trading on Wednesday, reaching $6.09. 2,557,717 shares of the company traded hands, compared to its average volume of 3,232,018. Amicus Therapeutics has a 52 week low of $5.51 and a 52 week high of $12.65. The stock has a 50-day moving average price of $6.07 and a 200 day moving average price of $7.77. The company has a debt-to-equity ratio of 2.02, a current ratio of 3.34 and a quick ratio of 2.47. The company has a market cap of $1.88 billion, a price-to-earnings ratio of -67.66 and a beta of 0.51.
About Amicus Therapeutics
(
Get Free ReportAmicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
Featured Articles
Before you consider Amicus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amicus Therapeutics wasn't on the list.
While Amicus Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
